An antioxidant transporter of the trace mineral selenium that protects against inflammatory bowel disease has the opposite effect in colorectal cancer, where it promotes tumor growth, researchers at Vanderbilt University Medical Center have reported.

Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Three Vanderbilt-Ingram Cancer Center physicians were recently named fellows of the American Society of Clinical Oncology.

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

An MRI method developed by Vanderbilt researchers uses imaging data to derive cell size and could be added to clinical practice for better monitoring of breast cancer treatment response.

A study from Vanderbilt researchers has found that enhanced treatment support can help smokers who have more difficulty quitting because they are fast metabolizers of nicotine.

The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.